explore -WSS

explore

author：leisure time 2025-09-28 20:32:43 - browse：2

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： FDA clears Verve to begin U.S. study of gene

hotspot

knowledge

explore

WSS

Roche drug slashes death risk in early

Results on Novartis prostate cancer therapy could expand its use

Will Ozempic

Roche acquires Telavant from Roivant, adding experimental IBD treatment

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

STAT Summit: Biotech founders on deal

leisure time

explore

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

STAT Summit: Michael J. Fox on progress in Parkinson's research

Peter Hotez and the public health issue of online harassment

STAT Readout: Friday, Oct. 20 biotech updates

Medical records are filled with copy

Beam Therapeutics to lay off 20% of its staff, re

Peter Hotez and the public health issue of online harassment

Why a market frenzy over new weight loss drugs defies logic

Guidelines to prevent youth baseball injuries need more muscle

FDA clears Verve to begin U.S. study of gene

hotspot

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Pharmacists can make shortage drugs, but at what cost?

The problems with dementia villages

STAT Summit: The economic case for universal basic health care

FDA struggles to regulate food additives, sometimes for decades

HHS leader on health, climate change and biopharma emissions

hotspot

knowledge

explore

hotspot